

1 **Laryngeal muscle activity during nasal high frequency oscillatory**  
2 **ventilation in non-sedated newborn lambs**

3  
4 Mohamed Amine Hadj-Ahmed, Nathalie Samson, Charlène Nadeau, Nadia Boudaa,  
5 Jean-Paul Praud

6 Neonatal Respiratory Research Unit, Departments of Pediatrics and Physiology,  
7 Université de Sherbrooke, QC, Canada, J1H 5N4

8  
9

10 **Running head:** High frequency ventilation and laryngeal muscle EMG

11

12 **Address for correspondence and proofs:**

13 Jean-Paul Praud MD PhD	Phone: (819) 346-1110, ext 14851
14 Departments of Pediatrics and Physiology	Fax: (819) 564-5215
15 Université de Sherbrooke	email: Jean-Paul.Praud@USherbrooke.ca
16 J1H 5N4, QC Canada	

17

18 **ABSTRACT**

19 Background - We have previously shown that nasal pressure support ventilation (nPSV)  
20 can lead to an active inspiratory laryngeal narrowing in lambs. This, in turn, can limit  
21 lung ventilation and divert air into the digestive system, with potentially deleterious  
22 consequences. On the other hand, nasal high frequency oscillatory ventilation (nHFOV)  
23 is particularly attractive in newborns, especially since, unlike nPSV, it does not require  
24 synchronization with the patient's inspiratory efforts.

25 Objectives - The main aim of the present study was to test the hypothesis that glottal  
26 constrictor muscle activity (EMG) does not develop during nHFOV. A secondary  
27 objective was to study laryngeal EMG during nHFOV-induced central apneas.

28 Methods - Polysomnographic recordings were performed in seven non-sedated lambs  
29 which were ventilated with increasing levels of nPSV and nHFOV at both 4 and 8 Hz, in  
30 random order. States of alertness, diaphragm and glottal muscle EMG, SpO<sub>2</sub> and  
31 respiratory movements were continuously recorded.

32 Results - While phasic inspiratory glottal constrictor EMG appeared with increasing  
33 nPSV levels in 6 out of 7 lambs, it was never observed with nHFOV. In addition, nHFOV  
34 at 4Hz dramatically inhibited central respiratory drive in 4/7 lambs, with 64 to 100% of  
35 recording time spent in central apnea in 3 lambs. No glottal constrictor EMG was  
36 observed during these central apneas.

37 Conclusion - nHFOV does not induce glottal constrictor muscle EMG in non-sedated  
38 newborn lambs, in contrast to nPSV. This may be an additional advantage of nHFOV  
39 relative to nPSV.

40 **KEYWORDS:** Nasal pressure support ventilation, nasal high frequency oscillatory  
41 ventilation, polysomnography, central apnea, quiet sleep.

42

43 **INTRODUCTION**

44 Non-invasive ventilation is increasingly used in the newborns to reduce the duration of  
45 endotracheal mechanical ventilation and its associated complications. Common  
46 indications in infants for non-invasive ventilation include respiratory distress syndrome,  
47 apneas of prematurity and respiratory syncytial virus infection [1,2].

48 In addition to the various conventional non-invasive ventilation modalities available,  
49 nHFOV is attracting increasing interest. First, it is well established that *endotracheal*  
50 HFOV is associated with less lung injury than conventional mechanical ventilation in  
51 animal studies [3], as well as with superior lung function at 11 to 14 years of age in  
52 extremely prematurely-born children [4]. Secondly, nHFOV does not require  
53 synchronization with the patient's respiratory efforts, a strong advantage in the newborn  
54 [5]. Thirdly, case reports in newborns, as well as bench studies using lung models, have  
55 shown that nasopharyngeal HFOV is highly effective in eliminating CO<sub>2</sub> [6,7]. Finally,  
56 animal data suggest that nasopharyngeal HFOV decreases lung inflammation and  
57 improves alveolarization compared to conventional ventilation [8].

58 However, an important consideration when using a nasal interface is the interposition of  
59 the larynx between the ventilator and the lungs. For instance, we have previously shown  
60 that nPSV can induce an active inspiratory laryngeal narrowing [9-11]. The latter may  
61 promote patient-ventilator asynchrony and limit lung ventilation [12], as well as divert the  
62 insufflated gas into the esophagus, exposing the infant to gastric distension and further  
63 respiratory compromise [13]. Knowing whether nHFOV can induce active laryngeal  
64 narrowing is certainly of interest before contemplating a more widespread use in  
65 newborns. Hence, the primary aim of our study was to assess the effects of nHFOV on

66 laryngeal EMG in non-sedated newborn lambs, testing the hypothesis that glottal  
67 narrowing does not develop during nHFOV.

68 Animal studies have demonstrated that *endotracheal* HFOV can inhibit spontaneous  
69 breathing and induce central apneas [14]. In addition, we have repeatedly shown the  
70 consistent presence of active glottal closure throughout central apneas in lambs [15].

71 Consequently, the secondary aims of the present study were to verify whether i)  
72 oscillation frequency changes during nHFOV induces central apneas and ii) active  
73 laryngeal closure is present during these nHFOV-induced central apneas.

74

## 75 **MATERIAL AND METHODS**

### 76 **Animals**

77 Experiments were conducted in seven term lambs aged from 4 to 5 days and weighing  
78 80 4.1 kg (SD 0.7). The study was approved by the ethics committee for animal care  
79 and experimentation of the Universite de Sherbrooke (# 037-10).

80

### 81 **Chronic instrumentation**

82 Surgery was performed under general anesthesia for chronic instrumentation (see 11 for  
83 details). We measured the electrical activity of the thyroarytenoid (EAta, a glottal  
84 constrictor), cricothyroid (EAct, a laryngeal dilator) and sternal diaphragmatic (EAdi)  
85 muscles, states of alertness, arterial blood gases, respiratory movements (inductance  
86 plethysmography), oxygen hemoglobin saturation (SpO<sub>2</sub>) and mask pressure (P<sub>mask</sub>).  
87 The raw EMG signals were sampled at 1000 Hz, band-pass filtered (30-300 Hz),  
88 rectified and moving time averaged (100 ms). All signals were transmitted *via*  
89 radiotelemetry and recorded using AcqKnowledge software (Santa Barbara, CA).

90

### 91 **Design of study**

92 Following 48 hours of rest, polysomnographic recordings were performed without  
93 sedation, while lambs were lying on their left side. Nasal PSV triggered by flow  
94 (Siemens Servo 300) and nHFOV (Sensormedics 3100a, Cardinal Health, Canada)  
95 were delivered *via* a custom-made nasal mask.

96 Following a first recording without ventilatory support (nCPAP 0), a nasal CPAP of 4  
97 cmH<sub>2</sub>O was applied. Then, nPSV and nHFOV were applied in a random order, using a

98 step-by-step increase in ventilation. Three levels of nPSV (6, 11 and 16 cmH<sub>2</sub>O above a  
99 PEEP of 4 cmH<sub>2</sub>O) were studied [9-11]. For nHFOV, preliminary experiments  
100 determined that while regular respiration was present at 8 Hz, respiration was frequently  
101 inhibited at 4 Hz. Hence, oscillatory frequency was first set at 8 Hz, mean airway  
102 pressure (MAP) at 8 cmH<sub>2</sub>O and inspiratory time at 33% [7,16]; thereafter, power levels  
103 were progressively increased to match nPSV levels. Accordingly, nHFOV-8Hz-  
104 corresponded to the power level ( $\Delta P$ -8Hz-1) at which abdominal vibrations were  
105 apparent, whereas nHFOV-8Hz-2 and nHFOV-8Hz-3 corresponded to  $\Delta P$ -8Hz-1 + 10 and  
106 + 20 cmH<sub>2</sub>O. Finally, nHFOV study was completed by reducing the oscillatory frequency  
107 to 4 Hz at nHFOV-4Hz-3. At least five minutes of quiet sleep (QS) were recorded in each  
108 condition.

109

## 110 **Data analysis**

111 States of alertness: Standard electrophysiological and behavioral criteria were used to  
112 recognize states of alertness. Only periods of QS were analyzed for laryngeal EMG with  
113 nPSV and nHFOV. However, for the second aims of our study, all states of alertness  
114 were analyzed.

## 115 Respiratory dependent variables

116 At each ventilatory level, the first 60 seconds of continuous QS were analyzed. The  
117 percentages of breaths with inspiratory phasic EMG of the TA (%inspiEAta) or CT  
118 (%inspiEAct) were calculated [11]. The inspiratory phasic EAdi and EAct amplitudes  
119 were expressed as a percentage of EAdi or EAct values averaged over 60 seconds  
120 during nCPAP 0 (respectively %ampliEAdi and %ampliEAct). Finally, the minute-EAdi

121 (inspiratory phasic EAdi x respiratory rate) was calculated. Values were averaged over  
122 60 seconds. Blood gases were measured at the end of each ventilatory level. A central  
123 apnea was defined as at least two missed breaths.

124

#### 125 **Statistical analysis**

126 Results were averaged in each lamb, then averaged for the 7 lambs as a whole, and  
127 described as means and SD. The Friedman test followed by the Wilcoxon signed rank  
128 test was used for all analyses (SPSS statistics 20). Differences were considered  
129 significant if  $P < 0.05$ . In addition, a  $P < 0.1$ , indicative of a tendency towards a  
130 significant difference, was fully considered in the discussion.

131



132 **RESULTS**

133 Experiments were completed in all lambs. Sample tracings obtained in one lamb are  
134 shown in figure 1.

135

136 **Alterations in respiration with increasing levels of nPSV and nHFOV at 8Hz**

137 A significant decrease in respiratory rate (RR) was observed with increasing levels of  
138 nPSV and nHFOV-8Hz (Table 1). Overall, RR was decreased with nPSV 20/4 compared  
139 to nPSV 15/4 ( $P = 0.03$ ), nPSV 10/4 ( $P = 0.02$ ) and nCPAP 4 ( $P = 0.08$ ). While no  
140 significant differences were observed between the various nHFOV-8Hz conditions ( $P =$   
141  $0.2$ ), RR was decreased in six lambs with nHFOV-8Hz-3 compared to MAP 8. A  
142 significant decrease in %ampliEAdi ( $P = 0.05$ ) and minute-EAdi ( $P = 0.04$ ) ( $n = 4$ ) was  
143 observed with increasing nPSV level, unlike nHFOV (Figure 2).

144 While PaCO<sub>2</sub> did not decrease during nHFOV ( $P = 0.9$ ), PaCO<sub>2</sub> was significantly  
145 decreased at the highest nPSV level (20/4) compared to nCPAP 4, nPSV 10/4 and  
146 nPSV 15/4 ( $P$  between 0.02 and 0.04). No alteration of PaO<sub>2</sub> was observed (Table 1).

147

148 **Laryngeal muscle activity with nPSV and nHFOV at 8Hz**

149 Similarly to our previous studies, phasic inspiratory EAta (glottal constrictor) appeared  
150 with increasing levels of nPSV in 6 of 7 lambs (Table 2). In addition, %inspiEAta  
151 increased in proportion with nPSV levels ( $P = 0.01$ ) (Figure 2). Simultaneously, a  
152 decrease in %inspiEAct and %ampliEAct (glottal dilator) was apparent with increasing  
153 levels of nPSV, although it did not reach statistical significance (respectively  $P \geq 0.6$ )  
154 (Figure 2). Conversely to nPSV, inspiEAta was never observed at any nHFOV-8Hz level

155 in any of the lambs (Table 2, Figure 2). Simultaneously, no significant alteration of  
156 baseline %inspiEAct and %ampliEAct activity was apparent with nHFOV<sub>-8Hz</sub> (Figure 2).

157

## 158 **Effects of nHFOV at 4Hz**

### 159 Respiratory inhibition

160 The effects of a decrease in oscillatory frequency from 8 to 4 Hz are displayed in figure  
161 1 and Table 3. Respiratory efforts were severely inhibited (> 60% recording time spent in  
162 apnea) in 3 of 7 lambs, including near total abolition of respiration throughout the  
163 recording in 2 lambs. Overall, the mean percentage of total time spent in apnea was  
164 higher at nHFOV<sub>-4Hz-3</sub> than nHFOV<sub>-8Hz-3</sub> (P = 0.02). In all lambs, regular respiration  
165 resumed when nHFOV<sub>-4Hz-3</sub> was ceased. Of note, despite the severe respiratory  
166 inhibition observed at nHFOV<sub>-4Hz-3</sub>, PaCO<sub>2</sub> remained above 35 mmHg for all lambs. In  
167 addition, PaCO<sub>2</sub> was not different at nHFOV<sub>-8Hz-3</sub> and nHFOV<sub>-4Hz-3</sub> (P = 0.4). Finally, the  
168 2 lambs with the most marked decrease in PaCO<sub>2</sub> from MAP 8 to nHFOV<sub>-4Hz-3</sub> (lambs 2  
169 and 5) had no respiratory inhibition at nHFOV<sub>-4Hz-3</sub>. Hence, overall, higher respiratory  
170 inhibition at nHFOV<sub>-4Hz-3</sub> compared to nHFOV<sub>-8Hz-3</sub> was clearly not linked to a lower  
171 PaCO<sub>2</sub> in the former condition.

### 172 Laryngeal muscle activity

173 As documented during nHFOV<sub>-8Hz</sub>, no inspiratory or expiratory EAta was observed at  
174 nHFOV<sub>-4Hz-3</sub> during periods with respiratory efforts. Finally, no continuous EAta was  
175 observed during any central apnea induced by nHFOV<sub>-4Hz-3</sub>.

176

177

178 **DISCUSSION**

179 This study demonstrates for the first time that in contrast to nPSV, nHFOV at 8 Hz or 4  
180 Hz did not induce phasic inspiratory glottal constrictor activity in any lamb.  
181 Simultaneously, phasic inspiratory glottal dilator activity did not decrease during nHFOV,  
182 unlike nPSV. In addition, nHFOV at 4Hz dramatically inhibited spontaneous breathing in  
183 half of the lambs, while nHFOV at 8Hz was responsible for a lesser decrease in  
184 respiratory rate.

185

186 **Respiration with nHFOV at 8 Hz**

187 The use of HFOV via a nasopharyngeal tube has been reported in newborns [5,17,18].  
188 Clinical interest in non-invasive HFOV stems from the fact that it does not require  
189 synchronization with the patient's breathing efforts [5]. In addition, HFOV is effective in  
190 eliminating CO<sub>2</sub> [6,7,19], while inducing less lung injury [3] and ensuring better alveolar  
191 development [8].

192 In agreement with observations in newborn infants [20], our results confirm that, aside  
193 from periods of prolonged central apneas which were especially prominent at 4 Hz (see  
194 infra), newborn lambs maintained regular respiration during nHFOV, with no significant  
195 modifications of baseline diaphragm activity.

196 Overall, blood gases were largely unaltered. The absence of hypocapnia may seem  
197 surprising, due to the reported ability of nHFOV to decrease CO<sub>2</sub> in newborn infants  
198 [6,7,19]. However, administration of nHFOV in these studies was for much longer  
199 periods than in our study, and the decrease in PaCO<sub>2</sub> was not apparent in the first two  
200 hours [7]. Further explanation may come from the absence of hypercapnia before

201 starting nHFOV in our lambs (except in one lamb), and the possibility of CO<sub>2</sub> re-  
202 inspiration [21].

203

#### 204 **Laryngeal muscle activity during nPSV and nHFOV**

205 The present study confirms our previous results in lambs that inspiEAta often develops  
206 against ventilator insufflations during nPSV, likely from the stimulation of  
207 bronchopulmonary receptors [9-11]. In contrast to nPSV, phasic inspiEAta was absent  
208 during nHFOV. While high amplitude changes in pressure, flow and volume are  
209 transmitted to lower airways and lungs during ventilator insufflations in nPSV, the  
210 situation is very different in nHFOV, where forced oscillations of very small volumes are  
211 superimposed on a constant positive pressure. Hence, differences in pattern stimulation  
212 of bronchopulmonary receptors may explain the differences in EAta activity in nPSV vs.  
213 nHFOV. In addition, while stimulation of upper airway mechanoreceptors did not appear  
214 to be involved in the activation of glottal constrictor muscles in nPSV [10], the reported  
215 oscillatory activation of these mechanoreceptors may play a role in preventing inspiEAta  
216 in nHFOV [22-24]. Finally, given that inspiEAta during nPSV appears related to a  
217 decrease in PaCO<sub>2</sub> in some lambs [11], the absence of hypocapnia in nHFOV may be  
218 involved in the absence of inspiEAta.

219 A few studies have suggested that HFOV may stimulate active upper airway opening  
220 [22,23]. In the present study however, no modification of inspiratory glottal dilator activity  
221 (EAct) was apparent with nHFOV. These results suggest that nHFOV prevents active  
222 laryngeal closure also by maintaining inspiratory EAct.

223

224 **Respiratory inhibiting effect 225 of nHFOV at 4Hz**

225 We observed that decreasing the oscillatory frequency from 8 to 4 Hz without altering  
226 MAP or Vt dramatically inhibited central inspiratory drive in almost all animals, without  
227 inducing hypocapnia. Similar respiratory inhibition reported with endotracheal HFOV has  
228 been linked to an increase in vagal pulmonary stretch receptor activity [14] as well as  
229 thoracic wall afferent activity [25]. While alterations of oscillation frequency, stroke  
230 volume or PaCO<sub>2</sub> have been deemed responsible for respiratory inhibition, our results  
231 show that alteration of frequency only in nHFOV can be sufficient.

232 **Laryngeal muscle activity during induced apneas**

233 Surprisingly, no continuous EA<sub>ta</sub> was observed during any central apnea induced by  
234 nHFOV at 4Hz. Our studies have consistently shown the presence of active glottal  
235 closure throughout neonatal central apneas under various conditions. The latter include  
236 spontaneous apneas in full-term and preterm lambs, hypocapnic induced apneas, as  
237 well as apneas during anoxic gasping [15]. To date, nHFOV is the only condition during  
238 which continuous active glottal closure was absent during central apneas in our neonatal  
239 ovine models. This cannot be related to the absence of hypocapnia since the latter was  
240 obviously absent in anoxic gasping [26]. Hence, it is rather related to afferent messages  
241 originating from airway and/or thoracic wall mechanoreceptors stimulated by the  
242 constant positive pressure (MAP at 8 cmH<sub>2</sub>O) and/or ventilator oscillations. Again, the  
243 effect of high frequency oscillations in opening the upper airways may explain the  
244 absence of EA<sub>ta</sub> during nHFOV-induced central apneas [22-24].

245

246 **CONCLUSION**

247 This is the first study documenting the effect of nHFOV on laryngeal muscle function and  
248 central inspiratory drive. In non-sedated newborn lambs, and contrary to nPSV, phasic  
249 inspiratory glottal constrictor activity is absent and phasic inspiratory glottal dilator  
250 activity is maintained during nHFOV. Moreover, nHFOV at 4 Hz often dramatically  
251 inhibits central inspiratory drive, even in the absence of alveolar hyperventilation.  
252 Further studies are needed to clarify the exact reflex mechanism underlying this  
253 respiratory inhibition. We propose that our results are relevant in helping the clinician  
254 choose the optimal nasal ventilatory modality for a given newborn in need of ventilatory  
255 support.

256

257 **ACKNOWLEDGMENTS**

258 The authors wish to fully acknowledge the excellent technical assistance of Charlene  
259 Nadeau and Jean-Philippe Gagne. This study was supported by an operating grant  
260 allocated to J-P Praud by the Canadian Institutes of Health Research. J-P Praud is the  
261 holder of the Canada Research Chair in Neonatal Respiratory Physiology and a member  
262 of the *Centre de recherche du Centre hospitalier universitaire de Sherbrooke*. M.A Hadj-  
263 Ahmed held a doctoral scholarship from the Foundation of Stars (Quebec) at the time of  
264 the study. The authors wish to greatly acknowledge the gracious lending of the  
265 Sormedics ventilator by Cardinal Health Canada.

266

267

## REFERENCES

268

1. Lazner MR, Basu AP, Klonin H: Non-invasive ventilation for severe bronchiolitis: analysis and evidence. *Pediatr Pulmonol* 2012; 47:909-916.

269

270

2. Ramanathan R, Sekar KC, Rasmussen M, Bhatia J, Soll RF: Nasal intermittent positive pressure ventilation after surfactant treatment for respiratory distress

271

272

syndrome in preterm infants <30 weeks' gestation: a randomized, controlled trial. *J*

273

*Perinatol* 2012; 32:336-343.

274

3. Yoder BA, Siler-Khodr T, Winter VT, Coalson JJ: High-frequency oscillatory

275

ventilation: effects on lung function, mechanics, and airway cytokines in the

276

immature baboon model for neonatal chronic lung disease. *Am J Respir Crit Care*

277

*Med* 2000; 162:1867-1876.

278

4. Zivanovic S, Peacock J, Alcazar-Paris M, Lo JW, Lunt A, Marlow N, Calvert S,

279

Greenough A: Late outcomes of a randomized trial of high-frequency oscillation in

280

neonates. *N Engl J Med* 2014; 20:1121-30.

281

5. Carlo WA: Should nasal high-frequency ventilation be used in preterm infants? *Acta*

282

*Paediatr* 2008; 97:1484-1485.

283

6. Mukerji A, Finelli M, Belik J: Nasal high-frequency oscillation for lung carbon dioxide

284

clearance in the newborn. *Neonatology* 2012; 103:160-164.

285

7. Czernik C, Schmalisch G, Buhrer C, Proquitte H: Weaning of neonates from

286

mechanical ventilation by use of nasopharyngeal high-frequency oscillatory

287

ventilation: a preliminary study. *J Matern Fetal Neonatal Med* 2012; 25: 374-378.

288

8. Null DM, Alvord J, Leavitt W, Wint A, Dahl MJ, Presson AP, Lane RH, DiGeronimo

289

RJ, Yoder BA, Albertine KH: High-frequency nasal ventilation for 21 d maintains gas



- 290 exchange with lower respiratory pressures and promotes alveolarization in preterm  
291 lambs. *Pediatr Res* 2014; 75:507-16.
- 292 9. Moreau-Bussiere F, Samson N, St-Hilaire M, Reix P, Lafond JR, Nsegbe E, Praud  
293 JP: Laryngeal response to nasal ventilation in nonsedated newborn lambs. *J Appl*  
294 *Physiol* 2007; 102:2149-2157.
- 295 10. Roy B, Samson N, Moreau-Bussiere F, Ouimet A, Dorion D, Mayer S, Praud JP:  
296 Mechanisms of active laryngeal closure during noninvasive intermittent positive  
297 pressure ventilation in nonsedated lambs. *J Appl Physiol* 2008; 105:1406-1412.
- 298 11. Hadj-Ahmed MA, Samson N, Bussieres M, Beck J, Praud JP: Absence of inspiratory  
299 laryngeal constrictor muscle activity during nasal neurally-adjusted ventilatory assist  
300 in newborn lambs. *J Appl Physiol* 2012; 113:63-70.
- 301 12. Oppersma E, Doorduyn J, van der Heijden EH, van der Hoeven JG, Heunks LM:  
302 Noninvasive ventilation and the upper airway: should we pay more attention? *Crit*  
303 *Care* 2013; 17:245.
- 304 13. Mahmoud RA, Roehr CC, Schmalisch G: Current methods of non-invasive  
305 ventilatory support for neonates. *Paediatr Respir Rev* 2011; 12:196-205.
- 306 14. Kohl J, Freund U, Koller EA: Reflex apnea induced by high-frequency oscillatory  
307 ventilation in rabbits. *Respir Physiol* 1991; 84:209-222.
- 308 15. Dorion D, Praud JP: The larynx and neonatal apneas. *Otolaryngol Head Neck Surg*  
309 2003; 128:463-469.
- 310 16. Muhlethaler V, Malcolm G. Mechanical ventilation in the newborn; a simplified  
311 approach: Part 2: high-frequency ventilation. *J Paediatr Child Health*, In press.

- 312 17. Dumas De La Roque E, Bertrand C, Tandonnet O, Rebola M, Roquand E, Renesne  
313 L, Elleau C: Nasal high frequency percussive ventilation versus nasal continuous  
314 positive airway pressure in transient tachypnea of the newborn: A pilot randomized  
315 controlled trial. *Pediatr Pulmonol* 2011; 46:218-223.
- 316 18. Colaizy TT, Younis UM, Bell EF, Klein JM: Nasal high-frequency ventilation for  
317 premature infants. *Acta Paediatr* 2008; 97:1518-1522.
- 318 19. Kneyber MC, Plotz FB, Sibarani-Ponsen RD, Markhorst DG: High-frequency  
319 oscillatory ventilation (HFOV) facilitates CO<sub>2</sub> elimination in small airway disease: the  
320 open airway concept. *Respir Med* 2005; 99:1459-1461.
- 321 20. PC: Allowing for spontaneous breathing during high-frequency oscillation: the key  
322 for final success? *Crit Care* 2006; 10:155.
- 323 21. Bostick AW, Naworol GA, Britton TJ, Ori TR, French SK, Derdak S: Inspiratory limb  
324 carbon dioxide entrainment during high-frequency oscillatory ventilation:  
325 characterization in a mechanical test lung and swine model. *Respir Care* 2012;  
326 57:1865-1872.
- 327 22. Henke KG, Sullivan CE: Effects of high-frequency oscillating pressures on upper  
328 airway muscles in humans. *J Appl Physiol* 1993; 75:856-862.
- 329 23. Plowman L, Lauff DC, Berthon-Jones M, Sullivan CE: Waking and genioglossus  
330 muscle responses to upper airway pressure oscillation in sleeping dogs. *J Appl*  
331 *Physiol* 1990; 68: 2564-2573.
- 332 24. Zhang S, Mathew OP: Response of laryngeal mechanoreceptors to high-frequency  
333 pressure oscillation. *J Appl Physiol* 1992; 73:219-223.

- 334 25. England SJ, Onayemi A, Bryan AC: Neuromuscular blockade enhances phrenic  
335 nerve activity during high-frequency ventilation. *J Appl Physiol* 1984; 56:31-34.
- 336 26. Thuot F, Lemaire D, Dorion D, Létourneau P, Praud JP: Active glottal closure during  
337 anoxic gasping in lambs. *Respir Physiol* 2001; 128:205-218.
- 338

339 **FIGURE LEGENDS**

340

341 **Figure 1:** Laryngeal muscle activity during nasal support ventilation (nPSV) and nasal  
342 high frequency oscillatory ventilation (nHFOV) at 8 Hz during quiet sleep in one lamb. In  
343 contrast to nPSV 15/4, nHFOV-8Hz-3 does not induce phasic inspiratory glottal constrictor  
344 electrical activity. Abbreviations from top to bottom: EAta, electrical activity (EA) of the  
345 thyroarytenoid muscle (ta, a glottal constrictor);  $\bar{J}$ EAta, moving time averaged EAta;  
346 EADi, EA of the diaphragm muscle; Pmask, mask pressure; Vlung, lung volume  
347 variations, given by the sum signal of the respiratory inductance plethysmography  
348 (inspiration upwards); I, inspiration; e, expiration. Arterial CO<sub>2</sub> pressure (PaCO<sub>2</sub>) is given  
349 in mmHg and heart rate (HR) in bpm. In addition to the inspiratory phasic EAta, which  
350 consistently occurred in lambs with nPSV in the present study as well as in our previous  
351 studies, expiratory phasic EAta was also uniquely observed in this lamb. Such expiratory  
352 EAta was very rarely observed in our previous studies on nPSV.

353

354 **Figure 2:** Glottal constrictor (EAta), glottal dilator (EAct) and diaphragmatic muscle  
355 electrical activity (EAdi) during nPSV and nHFOV-8Hz. A) Percentage of ventilatory  
356 cycles with EAta (%inspiEAta) for 6 lambs. B) Inspiratory phasic EAct amplitude  
357 (%ampliEAct) calculated for each inspiration and expressed as a percentage of EAct  
358 values during nCPAP 0 for 5 lambs C) Inspiratory phasic EAdi amplitude calculated for  
359 each inspiration and expressed as a percentage of EAdi values during nCPAP 0  
360 (%ampliEAdi), as well as minute-EAdi for 4 lambs. Increasing nPSV levels, as opposed  
361 to nHFOV, led to a progressive increase in %inspiEAta. While not statistically significant,

362 a decrease in %ampliEAct was apparent with increasing levels of nPSV, whereas this  
363 activity remained unchanged during nHFOV. Finally, a significant decrease in both  
364 %ampliEAdi and minute-EAdi was observed with increasing nPSV level, unlike nHFOV  
365 mode. Underlined exponent:  $P < 0.05$ ; normal font exponent:  $P < 0.1$  ∞: vs. CPAP 0; †:  
366 vs. PSV 10/4.; ‡: vs. PSV 15/4.

367

## TABLES

**Table 1: Respiratory variables during nasal pressure support ventilation and high frequency oscillatory ventilation**

	Baseline		nPSV: PIP/PEEP (cmH <sub>2</sub> O)			nHFOV			
	nCPAP 0	nCPAP 4	10/4	15/4	20/4	MAP 8	8Hz-1	8Hz-2	8Hz-3
<b>PaO<sub>2</sub> (mmHg)</b>	73 (9)	79 (12)	85 (15)	87 (19)	83 (24)	83 (13)	94 (30)	88 (12)	84 (15)
<b>PaCO<sub>2</sub> (mmHg)</b>	44 (8)	44 (8)	44 (7)	43 (8)	39 (8) <sup>a,b,c</sup>	46 (7)	44 (10)	45 (10)	44 (8)
<b>pHa</b>	7.41 (0.04)	7.39 (0.04)	7.37 (0.05)	7.39 (0.06)	7.43 (0.09) <sup>a,b</sup>	7.38 (0.05)	7.38 (0.05)	7.39 (0.04)	7.38 (0.04)
<b>RR (breaths/min)</b>	57 (17)	49 (19)	58 (34) <sup>c</sup>	42 (30)	36 (26) <sup>a,b,c</sup>	53 (34)	67 (59)	53 (53)	30 (12)
<b>Pmask (cm H<sub>2</sub>O)</b>	1 (1)	7 (1)	10 (1)	16 (1)	21 (1)	8 (1)	9 (4)	8 (2)	9 (2)

Values are reported as mean (standard deviation). nPSV: nasal pressure support ventilation; PIP: peak inspiratory pressure; PEEP: positive end-expiratory pressure; nHFOV: nasal high frequency oscillatory ventilation. nCPAP: nasal continuous positive airway pressure; MAP: mean airway pressure. 8Hz: oscillation frequency at 8 Hz, with 8Hz-1, 8Hz-2, 8Hz-3 indicating increasing power levels ( $\Delta P-1$ ,  $\Delta P-2$ ,  $\Delta P-3$ ); PaO<sub>2</sub>: arterial O<sub>2</sub> pressure; PaCO<sub>2</sub>: arterial CO<sub>2</sub> pressure; pHa: arterial pH; RR: respiratory rate; Pmask: mask pressure. Underlined exponent: p < 0.05; normal font exponent: p < 0.1. a: vs. CPAP 4; b: vs. PSV 10/4; c: vs. PSV 15/4.

368

369

**Table 2: Percentage of respiratory cycles with inspiratory phasic activity of the thyroarytenoid muscle and PaCO<sub>2</sub> during nasal pressure support ventilation or high frequency oscillatory ventilation in lambs during quiet sleep**

	Nasal Pressure: PIP/PEEP (cmH <sub>2</sub> O)						nHFOV power levels (cmH <sub>2</sub> O)							
	10/4		15/4		20/4		nHFOV <sub>-8Hz-1</sub>		nHFOV <sub>-8Hz-2</sub>		nHFOV <sub>-8Hz-3</sub>		nHFOV <sub>-4Hz-3</sub>	
	%inspiEAta	PaCO <sub>2</sub> mmHg	%inspiEAta	PaCO <sub>2</sub> mmHg	%inspiEAta	PaCO <sub>2</sub> mmHg	%inspiEAta	PaCO <sub>2</sub> mmHg	%inspiEAta	PaCO <sub>2</sub> mmHg	%inspiEAta	PaCO <sub>2</sub> mmHg	%inspiEAta	PaCO <sub>2</sub> mmHg
lamb 1	0	35.5	24	35.5	17	35.5	0	30	0	36.5	0	37.5	0	38.5
lamb 2	0	46	30	43.5	77	42.5	0	48	0	46	0	47	0	39
lamb 3	88	39	100	36.5	100	36.5	0	38.5	0	36.5	0	39.5	0	39.5
lamb 4	0	40.5	0	41.5	100	27.5	0	44	0	41.5	0	38.5	0	38.5
lamb 5	0	43.5	0	44.5	0	39	0	38	0	42	0	41	0	36.5
lamb 6	0	57.5	0	58.5	32	53.5	0	62.5	0	66	0	59.5	0	60.5
lamb 7	0	45	65	43	86	41.5	0	48	0	48	0	44	0	43

%inspiEAta: percentage of ventilatory cycles with EAta during inspiration. See table 1 for other abbreviations.

370

371

**Table 3: Effects of oscillatory frequency on respiratory efforts**

	nHFOV <sub>-8Hz-3</sub>						nHFOV <sub>-4Hz-3</sub>					
	time in apnea (s)	% time in apnea	% QS in apnea	% W in apnea	RR (/min)	ΔPaCO <sub>2</sub> (mmHg)	time in apnea (s)	% time in apnea	% QS in apnea	% W in apnea	RR (/min)	ΔPaCO <sub>2</sub> (mmHg)
<b>Lamb 1</b>	8/993	1	1	1	43	- 2	266/417	64	71	56	-	- 1
<b>Lamb 2</b>	0/541	0	0	0	28	- 1	11/917	1	1	3	26	- 9
<b>Lamb 3</b>	19/1041	2	0	4	29	- 1	340/340	100	100	100	-	- 1
<b>Lamb 4</b>	6/874	1	0	2	29	- 3	63/415	15	0	38	24	- 3
<b>Lamb 5</b>	4/463	1	2	0	39	- 2	10/411	2	0	8	33	- 7
<b>Lamb 6</b>	0/1222	0	0	0	40	- 2	97/353	27	16	62	-	- 1
<b>Lamb 7</b>	228/1158	20	19	28	7	- 3	373/432	86	85	95	-	- 4
<b>Mean ± SD</b>		3 ± 7	3 ± 7	5 ± 10	31 ± 12	- 2 ± 1		42 ± 41	39 ± 44	52 ± 38	28 ± 5	- 4 ± 3

Abbreviations: nHFOV<sub>-8Hz-3</sub> or <sub>-4Hz-3</sub>: nasal high frequency oscillatory ventilation at 8 Hz and 4 Hz respectively, with power level ΔP-3; time in apnea (s): total time spent in apnea during total recording; % time in apnea: percentage of total recording time spent in apnea; % QS (or W) in apnea: percentage of quiet sleep (or wakefulness) time spent in apnea; RR: respiratory rate calculated for each lamb presenting a % time in apnea less than 20%; ΔPaCO<sub>2</sub>: difference of PaCO<sub>2</sub> between MAP 8 and nHFOV<sub>-8Hz-3</sub> (or nHFOV<sub>-4Hz-3</sub>) conditions.


372

373

374



Figure 1



376

377

Figure 2:






Figure 3:

